# Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

> **NCT01588496** · PHASE2,PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 58 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01588496
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-05
- **Primary completion:** 2014-01-31
- **Final completion:** 2014-01-31
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588496, "Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01588496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*